Jazz Pharmaceuticals JAZZ Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's accounts receivable?
- Jazz Pharmaceuticals (JAZZ) reported accounts receivable of $836.3M in Q1 2026.
- How has Jazz Pharmaceuticals's accounts receivable changed year-over-year?
- Jazz Pharmaceuticals's accounts receivable increased by 28.1% year-over-year, from $652.99M to $836.3M.
- What is the long-term trend for Jazz Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accounts receivable has grown at a 15.9% compound annual growth rate (CAGR), from $396.49M to $830.7M.
- What does accounts receivable mean?
- The amount of money customers owe the company for products already delivered.
- How do you interpret accounts receivable?
- An increase relative to revenue may signal collection issues, while a decrease suggests efficient cash conversion cycles.
- How does accounts receivable compare across companies?
- Standard metric for all commercial-stage biopharma firms; benchmarked against Days Sales Outstanding (DSO).